Terms: = Lymphoma AND TAL2, Q16559, 6887 AND Treatment
5 results:
1. Primary central nervous system T-cell lymphoma: An analysis from the surveillance, epidemiology, and end results program.
Long H; Li S; Zhang Y; Li R; Fong T; Yang C; Wang H; Xu N; Xu Y; Wang K; Yang K; Qi S; Wang J
J Clin Neurosci; 2020 Sep; 79():74-79. PubMed ID: 33070923
[TBL] [Abstract] [Full Text] [Related]
2. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
Matsuda S; Suzuki R; Takahashi T; Suehiro Y; Tomita N; Izutsu K; Fukuhara N; Imaizumi Y; Shimada K; Nakazato T; Yoshida I; Miyazaki K; Yamaguchi M; Suzumiya J
Int J Hematol; 2020 Dec; 112(6):807-816. PubMed ID: 32880824
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin's lymphoma.
Fukunaga A; Okamoto Y; Shibata S; Inano S; Takiuchi Y; Yamamoto K; Tabata S; Kitano T
J Clin Exp Hematop; 2020 Jun; 60(2):37-40. PubMed ID: 32404568
[TBL] [Abstract] [Full Text] [Related]
4. Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?
Goldshtein A; Berger M
Crit Rev Oncog; 2014; 19(5):399-404. PubMed ID: 25404153
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia.
Ferrando AA; Neuberg DS; Dodge RK; Paietta E; Larson RA; Wiernik PH; Rowe JM; Caligiuri MA; Bloomfield CD; Look AT
Lancet; 2004 Feb; 363(9408):535-6. PubMed ID: 14975618
[TBL] [Abstract] [Full Text] [Related]
